Pharmacyclics Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMACYCLICS LLC, and when can generic versions of PHARMACYCLICS LLC drugs launch?
PHARMACYCLICS LLC has three approved drugs.
There are fifty-four US patents protecting PHARMACYCLICS LLC drugs.
There are three hundred and fifty-eight patent family members on PHARMACYCLICS LLC drugs in forty-eight countries and thirty-four supplementary protection certificates in fifteen countries.
Summary for Pharmacyclics Llc
| International Patents: | 358 |
| US Patents: | 54 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 3 |
| Patent Litigation for Pharmacyclics Llc: | See patent lawsuits for Pharmacyclics Llc |
Drugs and US Patents for Pharmacyclics Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | DISCN | Yes | No | 9,801,881*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | DISCN | Yes | No | 7,514,444*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | Yes | 9,296,753*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 10,752,634*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
International Patents for Pharmacyclics Llc Drugs
Supplementary Protection Certificates for Pharmacyclics Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2201840 | 233 5006-2015 | Slovakia | ⤷ Sign Up | PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
| 2529621 | 132017000036530 | Italy | ⤷ Sign Up | PRODUCT NAME: IBRUTINIB O SUO SALE FARMACEUTICAMENTE ACCETTABILE(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/4/945, 20150707 |
| 2526934 | 132016000119245 | Italy | ⤷ Sign Up | PRODUCT NAME: IBRUTINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE PER IL TRATTAMENTO DI PAZIENTI ADULTI CON LEUCEMIA LINFOCITICA CRONICA (CLL) PRECEDENTEMENTE NON TRATTATA(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/945, 20160530 |
| 2529621 | C20170010 00279 | Estonia | ⤷ Sign Up | PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 07.07.2015 |
| 2529621 | 300868 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707 |
| 2529621 | PA2017009 | Lithuania | ⤷ Sign Up | PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
